{
    "clinical_study": {
        "@rank": "154675", 
        "arm_group": {
            "arm_group_label": "Dutasteride Arm", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months)."
        }, 
        "brief_summary": {
            "textblock": "This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of\n      0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia\n      types III vertex, IV and V per the Norwood-Hamilton classification. The study consists of a\n      Screening Phase (3 weeks prior to Baseline) and a Treatment Phase (52 weeks). A subject who\n      completes the full course of study treatment and the final study visit (Week 52; Visit 7)\n      will be considered as study completion."
        }, 
        "brief_title": "A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alopecia", 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male outpatient, 20 to 50-years-old, inclusive (at the time of obtaining consent).\n\n          -  AGA classified as Type III vertex, IV, or V (excluding Type IV anterior and V\n             anterior) utilizing the Norwood-Hamilton classification.\n\n          -  Fluent and literate in Japanese with the ability to comprehend and record information\n             on the PAS SFI and DLQI questionnaires.\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2 x upper limit\n             of normal (ULN); alkaline phosphatase and bilirubin <=1.5 x ULN (isolated bilirubin\n             >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%).\n\n          -  Willing to comply with study requirements, including maintaining the same hair color\n             and hairstyle throughout the study- a) subjects who use hair colorants/hair dyes may\n             continue to do so; however, there should be no traces of hair color remaining on the\n             scalp at the time of study visits. b) hair length in nonbalding areas should be >=2\n             cm (0.75 inch) around the vertex region of the head at the time of study visits.\n\n          -  Able to swallow and retain oral medication\n\n        Exclusion Criteria:\n\n          -  Evidence of hypogonadism defined as serum testosterone <250 Nanogram/decilitre\n             (ng/dl) at Screening.\n\n          -  Unstable liver disease (chronic stable hepatitis B and C are acceptable if subject\n             otherwise meets entry criteria).\n\n          -  History of renal insufficiency or Serum creatinine >1.5 x ULN at Screening.\n\n          -  History of malignancy within the past 5 years, except basal cell or squamous cell\n             carcinoma of the skin.\n\n          -  History of prostate cancer before the age of 50 years in a first degree relative.\n\n          -  Serum PSA level >2.0 nanogram/millilitre (ng/mL) at Screening.\n\n          -  History of breast cancer or clinical breast examination suggestive of malignancy.\n\n          -  Active unstable thyroid disease, including subjects on therapy for either\n             hyperthyroidism or hypothyroidism unless their dose of thyroid medication has been\n             stable for at least 3 months.\n\n          -  Any unstable, serious co-existing medical condition(s) including, but not limited to,\n             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,\n             clinically evident congestive heart failure, or cerebrovascular accident within 6\n             months prior to Screening; uncontrolled diabetes or peptic ulcer disease which is\n             uncontrolled by medical management, and subjects who are known to be acquired\n             immunodeficiency syndrome [AIDS](including subjects with a diagnosis of human\n             immunodeficiency virus (HIV) positive).\n\n          -  History or current evidence of any serious and/or unstable pre-existing medical or\n             psychiatric disorder, or other conditions that could, in the opinion of the\n             investigator or GSK medical monitor, interfere with the subject's safety, obtaining\n             informed consent, or compliance with study procedures. Note: the investigator may\n             consult with GSK medical monitor if a condition could interfere with the subject's\n             safety.\n\n          -  Clinically relevant abnormal finding on the Screening electrocardiogram (ECG).\n\n          -  Global scalp hair thinning, including occipital areas.\n\n          -  Scarring of the scalp, including prior hair transplant or scalp reduction, or any\n             other condition or disease of the scalp or hair, including diseases of the hair shaft\n             (e.g., tinea infection, nonandrogenetic-cause of alopecia, psoriatic dermatitis or\n             other psoriatic lesions, or uncontrolled seborrheic dermatitis).\n\n          -  History of hair transplantation at any time to correct AGA or use of hair weaving\n             within 6 months prior to Screening.\n\n          -  History or evidence of hair loss other than AGA (e.g., due to an auto-immune,\n             endocrine, mechanical or infectious process, or secondary to a scalp dermatological\n             disorder).\n\n          -  Use of any cosmetic product aimed at improving or correcting the signs of hair loss\n             (e.g., scalp preparations with claims aiming at improved hair growth) within 2 weeks\n             prior to Screening.\n\n          -  Use of light or laser treatments on the scalp (e.g., light emitting diode [LED]\n             lamps) within 3 months prior to Screening.\n\n          -  Hypersensitivity to any 5 alpha-reductase (5AR) inhibitor or drugs chemically related\n             to the study treatment.\n\n          -  Use of Dutasteride within 18 months prior to Screening, or use of finasteride within\n             12 months prior to Screening.\n\n          -  Previous use of systemic cytotoxic agents.\n\n          -  Use of glucocorticoids (inhaled glucocorticoids are allowed; topical corticosteroids\n             are allowed provided that they are not used on the scalp) within 3 months prior to\n             Screening.\n\n          -  Use of the following during the 6 months prior to Screening: Minoxidil (oral or\n             topical), Carpronium chloride, Systemic drugs with anti-androgenic properties (e.g.,\n             cyproterone acetate, spironolactone, ketoconazole, flutamide, and bicalutamide). Use\n             of ketoconazole shampoo on the scalp is prohibited during the study, but use before\n             Screening is not a reason for exclusion. Cimetidine is prohibited during the study,\n             but use before Screening is not a reason for exclusion, Topical estrogen or\n             progesterone, Topical prostaglandin analogs on the scalp, Tamoxifen, Drugs\n             potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin,\n             psoralens), Drugs potentially causing hypotrichosis or telogen effluvium (e.g.,\n             valproic acid), Anabolic steroids, Lithium or phenothiazines.\n\n          -  Participation in any investigational or marketed drug or device trial within 1 month\n             prior to Screening for this study. Including participation in any trial for\n             Dutasteride and administration of active drugs (Dutasteride or finasteride) prior to\n             Screening for this study. In addition, subjects must not participate in any other\n             drug or device trials during the course of this study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831791", 
            "org_study_id": "114264"
        }, 
        "intervention": {
            "arm_group_label": "Dutasteride Arm", 
            "description": "Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.", 
            "intervention_name": "Dutasteride 0.5 mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dutasteride"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "male pattern hair loss", 
            "hair growth", 
            "hair restoration", 
            "Dutasteride", 
            "Androgenetic alopecia", 
            "safety", 
            "efficacy"
        ], 
        "lastchanged_date": "July 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "812-0025"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "532-0003"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "530-0057"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "103-0028"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "160-0022"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceutical and Medical Device Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AE (adverse event) is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Possible suicidality-related AE (PSRAE) is possibly related to suicidality as per Investigator's judgement.", 
                "measure": "Assessment of AEs, and PSRAEs", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Incidence of drug-related, treatment-emergent AEs", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "description": "The number and percentage of premature discontinuations will be assessed at 26 weeks and 52 weeks", 
                "measure": "Incidence of premature discontinuations", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "description": "An SAE (serious adverse event) is defined as any untoward medical occurrence that, at any dose: Results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect; all events of possible drug-induced liver injury with hyperbilirubinaemia; breast cancer in male subject; prostate cancer; spontaneous abortion in female partner of male subject.", 
                "measure": "Incidence of SAEs", 
                "safety_issue": "No", 
                "time_frame": "Up to 55 weeks"
            }, 
            {
                "description": "Clinical laboratory parameters including hematology, clinical chemistry and prostate-specific antigen (PSA) will be assessed at Screening, 26 weeks, and 52 weeks", 
                "measure": "Incidence of abnormal laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "Up to 55 weeks"
            }, 
            {
                "description": "Change from Baseline in vital signs for heart rate and systolic and diastolic blood pressure and change from Baseline in clinical laboratory for hematology, chemistry and PSA at Screening, 26 weeks, and 52 weeks will be assessed", 
                "measure": "Change from Baseline vital signs and clinical laboratory measurements to assess safety", 
                "safety_issue": "No", 
                "time_frame": "Screening and up to 55 weeks"
            }, 
            {
                "description": "Changes from Baseline in breast examination (such as breast enlargement and breast tenderness, a mass, or any signs suggestive of malignancy) at Screening, 26 weeks, and 52 weeks will be assessed", 
                "measure": "Change from Baseline in breast examination findings", 
                "safety_issue": "No", 
                "time_frame": "Screening and up to 55 weeks"
            }, 
            {
                "description": "Suicidality will be assessed at Baseline, 26 weeks, and 52 weeks using Columbia Suicide-Severity Rating Scale (C SSRS).", 
                "measure": "Assessment of suicidality using C SSRS", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from Baseline in target area and terminal area hair count within a 2.54-centimeter (cm) (1-inch) diameter circle at the vertex will be measured at Baseline, 26 weeks and 52 weeks, using macrophotographic technique. The target area and terminal area count will include nonvellus hair of >=30 micrometer (mcm) and terminal hair of >=60 mcm respectively using each macrophotograph.", 
                "measure": "Change from Baseline in target area and terminal area hair count to assess hair growth and restoration at 26 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 26 weeks"
            }, 
            {
                "measure": "Change from Baseline in target area and terminal area hair count to assess hair growth and restoration at 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 52 weeks"
            }, 
            {
                "measure": "Change from baseline in target area hair width to assess hair restoration at 26 weeks.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 26 weeks"
            }, 
            {
                "measure": "Change from baseline in target area hair width to assess hair restoration at 52 weeks.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 52 weeks"
            }, 
            {
                "description": "Panel global assessment of improvement will be measured to assess change in hair growth at Baseline, 26 weeks and 52 weeks using 7 point scale (1=greatly decreased, 7=greatly increased). The global photographs of the vertex and frontal views obtained at Baseline will be compared with 26 weeks and 52 weeks photographs.", 
                "measure": "Global assessment of improvement from baseline to 26 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 26 weeks"
            }, 
            {
                "measure": "Global assessment of improvement from baseline to 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 52 weeks"
            }, 
            {
                "description": "Investigator assessments includes change in stage of androgenetic alopecia (AGA) at Screening, 26 weeks and 52 weeks according to the Norwood-Hamilton classification", 
                "measure": "Change in stage of AGA according to the Norwood-Hamilton scale at 26 weeks", 
                "safety_issue": "No", 
                "time_frame": "Screening and Week 26"
            }, 
            {
                "measure": "Change in stage of AGA according to the Norwood-Hamilton scale at 52 weeks", 
                "safety_issue": "No", 
                "time_frame": "Screening and Week 55"
            }, 
            {
                "description": "Change in sexual functions will be assessed at Baseline, 13 weeks, 26 weeks, 39 weeks, and 52 weeks using Problem Assessment Scale of the Sexual Function Inventory (PAS SFI). Three questions are scored in a 5 point scale of 0 to 4 (0=big problem, 4=no problem). Total scores range from 0-12.", 
                "measure": "Change from Baseline in sexual problems assessed by PAS SFI", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Up to 52 weeks"
            }, 
            {
                "description": "Change in quality of life will be assessed at Baseline, 13 weeks, 26 weeks, 39 weeks, and 52 weeks using Dermatology Life Quality Index (DLQI). Ten items are scored in a 4 point scale (0=very much, 3=not at all). Total scores range from 0-30", 
                "measure": "Change from Baseline in quality of life assessed by DLQI", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 52 weeks"
            }, 
            {
                "description": "Blood samples for dihydrotestosterone (DHT) concentration will be collected at Screening, 26 weeks and 52 weeks", 
                "measure": "Measurement of serum DHT concentrations", 
                "safety_issue": "No", 
                "time_frame": "Up to 55 weeks"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}